Vivian Jiang, Ph.D.

Peer-Reviewed Articles

1. Li Y, McIntosh J, Jiang V, Yan F, Vargas J, Che Y, Wang W, Li CF, Fei Y, Lee C, Nie L, Yao Y, Wang M, Lee HH, Liu Y. BCL-2/BCL-X(L) dual inhibition triggers Gasdermin D-mediated pyroptosis in mantle cell lymphoma. Cancer Lett 632:217961, 2025. e-Pub 2025. PMID: 40754138.
2. Wang W, Cai Q, Liu Y, Nie L, Lee HH, Yan F, Fei Y, Yao Y, Li Y, Tan L, Lorenzi PL, Wang YN, Yao J, Chen Z, McIntosh J, Yu CT, Jain P, Jiang V, Vargas J, Li X, Zhang T, Li S, Santos D, Thirumurthi S, Seeley EH, Simon LM, Flowers CR, Ok CY, Wang ML. TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma. Blood, 2025. e-Pub 2025. PMID: 40700581.
3. Jiang V, Xue Y, Kim H, Cai Q, Zhang T, Nie L, McIntosh J, Liu Y, Chen H, Zhou J, Wang ML. YX0798 Is a Highly Potent, Selective, and Orally Effective CDK9 Inhibitor for Treating Aggressive Lymphoma. Blood Adv 9(19):4963-4976, 2025. e-Pub 2025. PMID: 40690748.
4. Jiang, C, Lee, W, Zhang, T, Jordan, A, Yan, F, Cai, Q, McIntosh, J, Vargas, J, Liu, Y, Wang, L. The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma. Biomarker Research 12(1), 2024. e-Pub 2024. PMID: 38886769.
5. Yan, F, Jiang, C, Jordan, A, Che, Y, Liu, Y, Cai, Q, Xue, Y, Li, Y, McIntosh, J, Chen, Z, Vargas, J, Nie, L, Yao, Y, Lee, H, Wang, W, Bigcal, J, Badillo, M, Meena, JK, Flowers, CR, Zhou, J, Zhao, Z, Simon, LM, Wang, L. The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma. Experimental Hematology and Oncology 13(1), 2024. e-Pub 2024. PMID: 38326887.
6. Li, Y, Lee, H, Jiang, C, Che, Y, McIntosh, J, Jordan, A, Vargas, J, Zhang, T, Yan, F, Simmons, ME, Wang, W, Nie, L, Yao, Y, Jain, P, Wang, M, Liu, Y. Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins. Cell Death and Disease 14(11), 2023. e-Pub 2023. PMID: 37919300.
7. Che Y, Liu Y, Li Y, McIntosh JM, Jordan A, Yan F, Wang W, Nie L, Lee HH, Jin J, Yao Y, Zhao Z, Jiang VC, Wang M. Dual targeting of CDK4/6 and Bcl-2 exhibits a potent anti-tumor effect on mantle cell lymphoma. Blood Adv 7(14):3361-3365, 2023. e-Pub 2023. PMID: 37257192.
8. Li L, Nie L, Jordan A, Cai Q, Liu Y, Li Y, Che Y, Vargas J, Chen Z, Leeming A, Wang W, Yao Y, Wang M, Jiang VC. Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica 108(6):1616-1627, 2023. e-Pub 2023. PMID: 36420799.
9. Liu Y, Yan F, Jiang VC, Li Y, Che Y, McIntosh J, Jordan A, Hou I, Nie L, Jin J, Wang W, Lee HH, Yao Y, Wang M. Pirtobrutinib and venetoclax combination overcomes resistance to targeted and CAR T-cell therapy in aggressive mantle cell lymphoma. Haematologica 108(5):1412-1416, 2023. e-Pub 2023. PMID: 36475521.
10. Jiang VC, Liu Y, Lian J, Huang S, Jordan A, Cai Q, Lin R, Yan F, McIntosh J, Li Y, Che Y, Chen Z, Vargas J, Badillo M, Bigcal JN, Lee HH, Wang W, Yao Y, Nie L, Flowers CR, Wang M. Co-targeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma. J Clin Invest 133(3), 2023. e-Pub 2023. PMID: 36719376.
11. Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y, Nie L, Liu Y, Jin J, Wang W, Lee HH, Che Y, Dai E, Han G, Wang R, Rai K, Futreal A, Flowers C, Wang L, Wang M. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer 21(1):185, 2022. e-Pub 2022. PMID: 36163179.
12. Ye H, Huang S, Liu Y, Chen Z, Wang M, Jiang VC. Dual targeting of PI3K and BCL-2 overcomes ibrutinib resistance in aggressive mantle cell lymphoma. J Cell Mol Med 26(10):3068-3073, 2022. e-Pub 2022. PMID: 35352453.
13. Jiang VC, Liu Y, Jordan A, Leeming A, McIntosh J, Huang S, Zhang R, Cai Q, Chen Z, Li Y, Che Y, Nie L, Karlsson I, Mårtensson L, Kovacek M, Teige I, Frendéus B, Wang M. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. J Hematol Oncol 15(1):42, 2022. e-Pub 2022. PMID: 35410313.
14. Huang S, Liu Y, Chen Z, Wang M, Jiang VC. PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma. Am J Cancer Res 12(3):1102-1115, 2022. e-Pub 2022. PMID: 35411248.
15. Jiang VC, Liu Y, Jordan A, McIntosh J, Li Y, Che Y, Jessen KA, Lannutti BJ, Wang M. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol 14(1):132, 2021. e-Pub 2021. PMID: 34454548.
16. Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun 12(1):2877, 2021. e-Pub 2021. PMID: 34001881.
17. Wu W, Wang W, Franzen CA, Guo H, Lee J, Li Y, Sukhanova M, Sheng D, Venkataraman G, Ming M, Lu P, Gao A, Xia C, Li J, Zhang LL, Jiang VC, Wang ML, Andrade J, Zhou X, Wang YL. Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. Blood Adv 5(1):185-197, 2021. e-Pub 2021. PMID: 33570628.
18. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
19. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. e-Pub 2020. PMID: 32191807.
20. Wang J, Wang J, Lopez E, Guo H, Zhang H, Liu Y, Chen Z, Huang S, Zhou S, Leeming A, Zhang RJ, Jung D, Shi H, Grundman H, Doakes D, Cui K, Jiang C, Ahmed M, Nomie K, Fang B, Wang M, Yao Y, Zhang L. Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma. Blood Cancer J 9(12):95, 2019. e-Pub 2019. PMID: 31780660.
21. Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, Huang S, Li CJ, Lorence E, Zhou S, Gong T, Jiang C, Ahmed M, Yao Y, Nomie KJ, Zhang L, Wang M. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene 38(11):1802-1814, 2019. e-Pub 2019. PMID: 30361685.
22. Li CJ, Jiang C, Liu Y, Bell T, Ma W, Ye Y, Huang S, Guo H, Zhang H, Wang L, Wang J, Nomie K, Zhang L, Wang M. Pleiotropic action of novel Bruton's tyrosine kinase inhibitor BGB-3111 in mantle cell lymphoma. Mol Cancer Ther 18(2):267-277, 2019. e-Pub 2019. PMID: 30413649.
23. Zheng G, Jiang C, Li Y, Yang D, Ma Y, Zhang B, Li X, Zhang P, Hu X, Zhao X, Du J, Lin X. TMEM43-S358L mutation enhances NF-κB-TGFβ signal cascade in arrhythmogenic right ventricular dysplasia/cardiomyopathy. Protein Cell 10(2):104-119, 2019. e-Pub 2019. PMID: 29980933.
24. Wang T, Fan C, Yao A, Xu X, Zheng G, You Y, Jiang C, Zhao X, Hou Y, Hung MC, Lin X. The adaptor protein CARD9 protects against colon cancer by restricting mycobiota-mediated expansion of myeloid-derived suppressor cells. Immunity 49(3):504-514.e4, 2018. e-Pub 2018. PMID: 30231984.
25. Huang S, Jiang C, Zhang H, Bell T, Guo H, Liu Y, Yao Y, Zeng D, Ahmed M, Nomie K, Zhang L, Wang M. The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J 8(3):33, 2018. e-Pub 2018. PMID: 29559616.
26. Liu Y, Yin Y, Zhang Z, Li CJ, Zhang H, Zhang D, Jiang C, Nomie K, Zhang L, Wang ML, Zhao G. Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity. Eur J Med Chem 138:543-551, 2017. e-Pub 2017. PMID: 28704757.
27. Jiang, C, Zhu, Y, Zhou, Z, Gumin, J, Bengtsson, L, Wu, W, Songyang, Z, Lang Jr, FF, Lin, X. TMEM43/LUMA is a key signaling component mediating EGFR-induced NF-κ B activation and tumor progression. Oncogene 36(20):2813-2823, 2017. e-Pub 2017. PMID: 27991920.
28. Zhao X, Guo Y, Jiang C, Chang Q, Zhang S, Luo T, Zhang B, Jia X, Hung MC, Dong C, Lin X. JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression. Nat Med 23(3):337-346, 2017. e-Pub 2017. PMID: 28112734.
29. Wang T, Pan D, Zhou Z, You Y, Jiang C, Zhao X, Lin X. Dectin-3 deficiency promotes colitis development due to impaired antifungal innate immune responses in the gut. PLoS Pathog 12(6):e1005662, 2016. e-Pub 2016. PMID: 27280399.
30. Jiang C, Zhou Z, Quan Y, Zhang S, Wang T, Zhao X, Morrison C, Heise MT, He W, Miller MS, Lin X. CARMA3 is a host factor regulating the balance of inflammatory and antiviral responses against viral infection. Cell Rep 14(14):2389-2401, 2016. e-Pub 2016. PMID: 26947079.
31. Pan D, Jiang C, Ma Z, Blonska M, You MJ, Lin X. MALT1 is required for EGFR-induced NF-κB activation and contributes to EGFR-driven lung cancer progression. Oncogene 35(7):919-28, 2016. e-Pub 2016. PMID: 25982276.
32. Pan D, Zhu Y, Zhou Z, Wang T, You H, Jiang C, Lin X. The CBM complex underwrites NF-kappaB activation to promote HER2-associated tumor malignancy. Mol Cancer Res 14(1):93-102, 2016. e-Pub 2016. PMID: 26392569.
33. Zhao, X, Zhu, L, Chang, Q, Jiang, C, You, Y, Luo, T, Jia, XM, Lin, X. C-type lectin receptor Dectin-3 mediates trehalose 6,6′-dimycolate (TDM)-induced Mincle expression through CARD9/Bcl10/MALT1-dependent nuclear factor (NF)-κB activation. Journal of Biological Chemistry 289(43):30052-30062, 2014. e-Pub 2014. PMID: 25202022.
34. Zhu LL, Zhao XQ, Jiang C, You Y, Chen XP, Jiang YY, Jia XM, Lin X. C-type lectin receptors Dectin-3 and Dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. Immunity 39(2):324-34, 2013. e-Pub 2013. PMID: 23911656.
35. Jiang T, Grabiner B, Zhu Y, Jiang C, Li H, You Y, Lang J, Hung MC, Lin X. CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression. Cancer Res 71(6):2183-92, 2011. e-Pub 2011. PMID: 21406399.
36. Jiang C, Komazin-Meredith G, Tian W, Coen DM, Hwang CB. Mutations that increase DNA binding by the processivity factor of herpes simplex virus affect virus production and DNA replication fidelity. J Virol 83(15):7573-80, 2009. e-Pub 2009. PMID: 19474109.
37. Jiang C, Hwang YT, Wang G, Randell JC, Coen DM, Hwang CB. Herpes simplex virus mutants with multiple substitutions affecting DNA binding of UL42 are impaired for viral replication and DNA synthesis. J Virol 81(21):12077-9, 2007. e-Pub 2007. PMID: 17715219.
38. Jiang C, Hwang YT, Randell JC, Coen DM, Hwang CB. Mutations that decrease DNA binding of the processivity factor of the herpes simplex virus DNA polymerase reduce viral yield, alter the kinetics of viral DNA replication, and decrease the fidelity of DNA replication. J Virol 81(7):3495-502, 2007. e-Pub 2007. PMID: 17229696.
39. Jiang C, Hwang YT, Hwang CB. Herpes simplex virus type 1 recombinants without the oriL sequence replicate DNA with increased fidelity. Virology 347(2):277-85, 2006. e-Pub 2006. PMID: 16427677.
40. Corcoran CA, Luo X, He Q, Jiang C, Huang Y, Sheikh MS. Genotoxic and endoplasmic reticulum stresses differentially regulate TRB3 expression. Cancer Biol Ther 4(10):1063-7, 2005. e-Pub 2005. PMID: 16294033.
41. Randell JC, Komazin G, Jiang C, Hwang CB, Coen DM. Effects of substitutions of arginine residues on the basic surface of herpes simplex virus UL42 support a role for DNA binding in processive DNA synthesis. J Virol 79(18):12025-34, 2005. e-Pub 2005. PMID: 16140778.
42. Li J, Wen Y, Jiang C, Li F and Gao C. A simple and rapid method for isolating mitochondrial plasmid DNA from plants. Acta Scientiarum 33(4):49-52, 2000. e-Pub 2000.

Invited Articles

1. Jiang C, Lin X. Regulation of NF-kB by the CARD proteins. Immunol Rev 246(1):141-53, 2012. e-Pub 2012. PMID: 22435552.

Other Articles

1. Yan, F, Jiang, C, Jordan, A, Che, Y, Liu, Y, Cai, Q, Xue, Y, Li, Y, McIntosh, J, Chen, Z, Vargas, J, Nie, L, Yao, Y, Lee, H, Wang, W, Bigcal, J, Badillo, M, Meena, JK, Flowers, CR, Zhou, J, Zhao, Z, Simon, LM, Wang, L Correction. Experimental Hematology and Oncology 15(1), 2026. PMID: 41668106.
2. Jiang VC Milestones and challenges in targeting BTK: a journey from kinase inhibitors to protein degraders. TPD Symposium.

Abstracts

1. Xue Y, Jiang V, Chen H, Kim H, Zhang T, Cai Q, Nie L, McIntosh J, Liu Y, Wang M, Zhou J. Drug discovery of potent and specific CDK9 protein degraders for the treatment of refractory lymphomas. AACR, 2025. e-Pub 2025.
2. Jiang V, Xue Y, Kim H, Cai Q, Zhang T, Nie L, McIntosh J, Liu Y, Chen H, Santos D, Thirumurthi S, Zhou J, Wang M. Orally Effective CDK9 Inhibitor YX0798 for Treating Aggressive Lymphoma. ASH, 2024. e-Pub 2024.
3. Nie L, Jiang V, Liu Y, Zhang T, Kim H, Vargas J, Cai Q, Thirumurthi S, Santos D, Wang M. Evaluating Full Antitumor Activities of Monoclonal Antibody and Innate Immune Cells in Relapsed/Refractory Mantle Cell Lymphoma Using Ex Vivo Organoid Platform. ASH, 2024. e-Pub 2024.
4. Jiang VC, Xue Y, Kim H, McIntosh J, Chen H, Zhang T, Liu Y, Zhou J, Wang M. Targeting CDK9 with a novel potent and selective inhibitor, YX0798, in CAR-T-relapsed mantle cell lymphoma models. AACR, 2024. e-Pub 2024.
5. Jiang VC. The Selective CDK9 Inhibitor VIP152 Overcame Therapeutic Resistance in Mantle Cell Lymphoma. ASH, 2023. e-Pub 2023.
6. Liu Y, Li Y, Lee H, McIntosh J, Wang W, Yan F, Jiang V, Nie L, Yao Y, Wang M. BV6, AN ANTAGONIST OF INHIBITOR OF APOPTOSIS PROTEINS, SENSITIZES RESISTANT MANTLE CELL LYMPHOMA CELLS TO VENETOCLAX. AACR, 2023. e-Pub 2023.
7. Jiang VC, Liu Y, Cai Q, McIntosh JM, Li Y, Chen Z, Lee H, Wang W, Yao Y, Nie L, Wang M. BTK and MALT1 are critical for cell adhesion and dissemination in mantle cell lymphoma. AACR, 2023. e-Pub 2023.
8. Jiang VC, Yan F, Jordan AA, Che Y, Liu Y, Cai Q, Li Y, McIntosh J, Chen Z, Vargas J, Yao Y, Lee H, Jin J, Wang W, Nie L, Zhao Z, Simon LM, Wang ML. Targeting the HSP90-MYC-CDK9 axis to overcome dual resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma. ASH, 2022. e-Pub 2022.
9. Nie L, Liu Y, Jiang C, Che Y, Jin J, Cai Q, Wang W, Li Y, Jordan AA, McIntosh J, Vargas J, Yao Y, Lee H, Wang ML. Establishment of a Patient-Derived Organoid Culture Platform for Mantle Cell Lymphoma Drug Sensitivity and CAR T Cell Anti-Tumor Activity Assay. ASH, 2022. e-Pub 2022.
10. Che Y, Wang W, Liu Y, Lee H, Li Y, Chen Z, McIntosh J, Jiang C, Yao Y, Wang M. HSP27 Promotes Mantle Cell Lymphoma Growth and Mediates Resistance to Venetoclax. ASH, 2022. e-Pub 2022.
11. Jiang VC, Hao D, Jain P, Li Y, Cai Q, Liu Y, Che Y, Vargas J, Yao Y, Nie L, Dai E, Han G, Wang R, Rai K, Futreal A, Flowers C, Wang L, Wang M. Multi-omics profiling can predict for relapse and response to brexucabtagene autoleucel CAR T-cell therapy in patients with mantle cell lymphoma. AACR, 2022. e-Pub 2022.
12. Jiang VC, Li L, Jordan A, Xue Y, Yan F, McIntosh J, Liu Y, Che Y, Li Y, Cai Q, Leeming A, Simon L, Zhao Z, Zhou J, Wang M. Targeting transcription elongation via CDK9 in mantle cell lymphoma patients with dual resistance to BTK inhibition and CAR T therapy. AACR, 2022. e-Pub 2022.
13. Che Y, Liu Y, Li Y, McIntosh J, Jordan AA, Chen Z, Yan F, Wang W, Jin J, Jiang C, Yao Y, Wang M. Abemaciclib in combination with copanlisib to overcome therapeutic resistance in mantle cell lymphoma. ASH, 2021. e-Pub 2021.
14. Nie L, Liu Y, Che Y, Li Y, Wang W, Jin J, Cai Q, Vargas J, McIntosh J, Jordan AA, Jiang VC, Yao Y, Wang M. Establishment of patient-derived organoid culture platform of mantle cell lymphoma. ASH, 2021. e-Pub 2021.
15. Jiang VC, Cai Q, Hao D, Liu Y, Li Y, Che Y, McIntosh J, Jordan AA, Chen Z, Leeming A, Nie L, Wang L, Wang M. Single cell transcriptomic profiling of patient-derived xenografts of mantle cell lymphoma reveals a special tumor cell population: seed cells for disease dissemination and progression. ASH, 2021. e-Pub 2021.
16. Yan F, Jiang C, Cai Q, Jain P, Li Y, Liu Y, McIntosh J, Jordan AA, Zhao Z, Simon L, Wang M. Dynamic reprogramming and evolution associated with sequential resistance to ibrutinib and CAR T therapy in mantle cell lymphoma. ASH, 2021. e-Pub 2021.
17. Li Y, Liu Y, Che Y, Jordan AA, McIntosh J, Leeming A, Andersen CL, Cidado J, Jin J, Jiang VC, Wang M. Dual targeting Bcl-2 by venetoclax and MCL-1 by AZD5991 to overcome therapeutic resistance in aggressive R/R mantle cell lymphoma. ASH, 2021. e-Pub 2021.
18. Li Y, Liu Y, Che Y, McIntosh J, Jordan AA, Leeming A, Andersen CL, Cidado J, Jin J, Jiang VC, Wang M. Combination therapy of BCL-2/XL dual inhibitor AZD0466 with acalabrutinib to overcome therapeutic resistance in aggressive R/R mantle cell lymphoma. ASH, 2021. e-Pub 2021.
19. Liu Y, Jiang C, Yan F, McIntosh J, Jordan AA, Li Y, Che Y, Cai Q, Wang W, Nie L, Wang M. Pirtobrutinib overcomes ibrutinib and venetoclax resistance in mantle cell lymphoma. ASH, 2021. e-Pub 2021.
20. Jordan AA, McIntosh J, Liu Y, Leeming A, Lee W, Karlsson I, Mårtensson L, Kovacek M, Teige I, Frendéus B, Wang M, Jiang C. Targeting antibody checkpoint FcγRIIb using monoclonal antibody BI-1206 to overcome therapeutic resistance in mantle cell lymphoma. ASH, 2020. e-Pub 2020.
21. Che Y, Liu Y, PhD, Li L, Hill H, McIntosh J, BS, Jordan AA, BS, Jung D, Yao Y, PhD, Jiang VC, PhD, Wang M, MD. Abemaciclib-based combinational therapies to overcome therapeutic resistance in mantle cell lymphoma. ASH, 2020. e-Pub 2020.
22. Liu Y, Zhao S, Jiang CC, Yao Y, McIntosh J, Jordan AA, Li Y, Che Y, Jain P, Wang L, Wang M. Interrogation of dysregulated pathways enables precision medicine in mantle cell lymphoma. ASH, 2020. e-Pub 2020.
23. Jiang VC, Lian J, Huang S, Zhang S, Liu Y, Wang L, Wang M. Oncogenic MALT1 promotes cell survival and mediates ibrutinib resistance and ibrutinib-venetoclax resistance in mantle cell lymphoma. ASH, 2020. e-Pub 2020.
24. Li Y, Liu Y, McIntosh J, Jordan AA, Leeming A, Andersen CL, Cidado J, Jiang VC, Wang M. AZD4320 is a novel and potent BCL-2/xL dual inhibitor in targeting aggressive mantle cell lymphoma. ASH, 2020. e-Pub 2020.
25. Jiang VC, Zhang S, Zhao S, Liu Y, McIntosh J, Wang L, Wang M. Xeno-MCL: Genomic, transcriptomic and pathologic landscape associated with disease progression, clonal evolution and tissue tropism in patient-derived xenografts of mantle cell lymphoma. ASH, 2020. e-Pub 2020.
26. Liu Y, Jiang VC, McIntosh J, Jordan AA, Li Y, Wang M. Overcoming CAR T resistance with non-covalent BTK inhibitor LOXO-305 in mantle cell lymphoma. ASH, 2020. e-Pub 2020.
27. Jiang VC, Zhang S, Lian J, Wang Y, Zhang R, Liu Y, McIntosh J, Han G, Wang R, Santos D, Leeming A, Chen Z, Hartig K, Bigcal J, Lee H, Steiner RE, Romaguera JE, Jain P, Nomie K, Futreal A, Wang L, Wang M. Single cell transcriptomic evolution and resistance mechanisms of BTK and BCL-2 inhibition in mantle cell lymphoma. ASH, 2020. e-Pub 2020.
28. Jordan AA, McIntosh J, Liu Y, Leeming A, Lee W, Karlsson I, Mårtensson L, Kovacek M, Teige I, Frendéus B, Wang M, Jiang C. Targeting antibody checkpoint FcγRIIB using monoclonal antibody BI-1206 to overcome therapeutic resistance in mantle cell lymphoma. ASH, 2020. e-Pub 2020.
29. Jiang VC, Liu Y, McIntosh J, Jordan AA, Leeming A, Chen Z, Jessen KA, Lannutti BJ, Wang M. Targeting ROR1 using the antibody drug conjugate VLS-101 in aggressive mantle cell lymphoma. ASH, 2020. e-Pub 2020.
30. Lian J, Xue Y, Jordan AA, McIntosh J, Liu Y, Wang M, Zhou J, Jiang VC. Targeting transcription checkpoint using a novel CDK9 inhibitor in mantle cell lymphoma. ASH, 2020. e-Pub 2020.
31. Li L, Jiang C, Navsaria LJ, Liu Y, Leeming A, Wang M, Yao Y. Targeting glutamine metabolism overcomes resistance to targeted therapies in refractory mantle cell lymphoma. ASH, 2020. e-Pub 2020.
32. Jiang C, Zhang S, Wang Y, Zhang R, Liu Y, McIntosh J, Han G, Wang R, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Lee H, Steiner R, Romaguera J, Jain P, Nomie K, Futreal A, Wang L, Wang M. Single-cell RNA-seq reveals heterogeneity, clonal evolution and strategies to overcome ibrutinib-venetoclax dual resistance in mantle cell lymphoma. AACR, 2020. e-Pub 2020.
33. Jiang C, Zhang R, Zhang S, Lee W, Huang S, Liu Y, Leeming A, McIntosh JM, Jain P, Nomie K, Wang L, Wang ML. Targeting PI3K and PLK1 to overcome ibrutinib-venetoclax resistance in mantle cell lymphoma. ASH, 2019. e-Pub 2019.
34. Jiang C, Liu Y, McIntosh JM, Leeming A, Zhang R, Lee W, Nomie K, Karlsson I, Mårtensson L, Kovacek M, Teige I, Frendéus B, Wang ML. BI-1206, a monoclonal antibody against FcγRIIb, showed superior anti-tumor activity in an ibrutinib-venetoclax dual resistant PDX model in mantle cell lymphoma. ASH, 2019. e-Pub 2019.
35. Jiang C, Liu Y, McIntosh JM, Leeming A, Zhang R, Lee W, Nomie K, Karlsson I, Mårtensson L, Kovacek M, Teige I, Frendéus B, Wang ML. BI-1206, a monoclonal antibody against FcγRIIb, showed superior anti-tumor activity in an ibrutinib-venetoclax dual resistant PDX model in mantle cell lymphoma. ASH, 2019. e-Pub 2019.
36. Jiang C, Zhang S, Huang S, Liu Y, Zhang R, Leeming A, McIntosh JM, Lee W, Nomie K, Wang L, Wang ML. PDOX models empower preclinical drug evaluation and mechanistic studies via faithful recapitulation of the pathology, complex heterogeneity, genetic-transcriptomic landscape, and therapeutic response of mantle cell lymphoma. ASH, 2019. e-Pub 2019.
37. Zhang R, Lee W, HUang S, Liu Y, Leeming AH, McIntosh J, Nome K, Jiang VC, Wang M. Copanlisib and volasertib overcome ibrutinib-venetoclax resistance via targeting PI3K-AKT signaling and G/2M cell cycle transition in mantle cell lymphoma. ASH, 2019. e-Pub 2019.
38. Ye H, Huang S, Jung D, Jiang C, Nomie K, Zhang L, Wang M. Simultaneous Inhibition of BCL-2 and PI3K Signaling Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma. ASH, 2018. e-Pub 2018.
39. Jiang C, Huang S, Liu Y, Nomie K, Zhang L, Wang M. Dual targeting of BTK and PLK1 causes lethal synergistic effects in mantle cell lymphoma. AACR, 2018. e-Pub 2018.
40. Jiang C, Huang S, Liu Y, Li C, Guo H, Wang J, Lopez E, Zhang H, Lorence EA, Merolle M, Balaji S, Ahmed M, Nomie K, Lin X, Zhang L, Wang M. Targeting the Paracaspase MALT1: A Potential Therapy to Overcome Ibrutinib Resistance in Relapsed/Refractory Mantle Cell Lymphoma Patients. ASH, 2017. e-Pub 2017.
41. Jiang C, Huang S, Lin X, Wang M, Zhang L. Targeting the paracaspase MALT1: A potential therapy to overcome ibrutinib resistance in relapsed/refractory MCL patients. AACR, 2017. e-Pub 2017.

Book Chapters

1. Jiang C, Lin X. Analysis of epidermal growth factor-induced NF-κB signaling. In: Methods Mol Biol, 75-102, 2015.

Web Publications

1. Wang Y, Wang R, Zhang S, Song S, Jiang C, Han G, Wang M, Ajani J, Futreal A, Wang L. iTALK: an R Package to Characterize and Illustrate Intercellular Communication, 2019.

Patents

1. Wang M, Zhou J, Jiang V, Zhou M. MALT1 AND BTK DUAL INHIBITORS, 2025. Patent Number: WO/2025/174889.